Cargando…

The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients

Recent data suggest that the type of anesthesia used during the resection of solid tumors impacts the long-term survival of patients favoring total-intravenous-anesthesia (TIVA) over inhalative-anesthesia (INHA). Here we sought to query this impact on survival in patients undergoing resection of gli...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmoch, Thomas, Jungk, Christine, Bruckner, Thomas, Haag, Sabine, Zweckberger, Klaus, von Deimling, Andreas, Brenner, Thorsten, Unterberg, Andreas, Weigand, Markus A., Uhle, Florian, Herold-Mende, Christel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490243/
https://www.ncbi.nlm.nih.gov/pubmed/33354749
http://dx.doi.org/10.1007/s10143-020-01452-7
_version_ 1784578491326398464
author Schmoch, Thomas
Jungk, Christine
Bruckner, Thomas
Haag, Sabine
Zweckberger, Klaus
von Deimling, Andreas
Brenner, Thorsten
Unterberg, Andreas
Weigand, Markus A.
Uhle, Florian
Herold-Mende, Christel
author_facet Schmoch, Thomas
Jungk, Christine
Bruckner, Thomas
Haag, Sabine
Zweckberger, Klaus
von Deimling, Andreas
Brenner, Thorsten
Unterberg, Andreas
Weigand, Markus A.
Uhle, Florian
Herold-Mende, Christel
author_sort Schmoch, Thomas
collection PubMed
description Recent data suggest that the type of anesthesia used during the resection of solid tumors impacts the long-term survival of patients favoring total-intravenous-anesthesia (TIVA) over inhalative-anesthesia (INHA). Here we sought to query this impact on survival in patients undergoing resection of glioblastoma (GBM). All patients receiving elective resection of a newly diagnosed, isocitrate-dehydrogenase-1-(IDH1)-wildtype GBM under general anesthesia between January 2010 and June 2017 in the Department of Neurosurgery, Heidelberg University Hospital, were included. Patients were grouped according to the applied anesthetic technique. To adjust for potential prognostic confounders, patients were matched in a 1:2 ratio (TIVA vs. INHA), taking into account the known prognostic factors: age, extent of resection, O-6-methylguanine-DNA-methyltransferase-(MGMT)-promoter-methylation-status, pre-operative Karnofsky-performance-index and adjuvant radio- and chemotherapy. The primary endpoint was progression-free-survival (PFS) and the secondary endpoint was overall-survival (OS). In the study period, 576 patients underwent resection of a newly diagnosed, IDH-wildtype GBM. Patients with incomplete follow-up-data, on palliative treatment, having emergency or awake surgery; 54 patients remained in the TIVA-group and 417 in the INHA-group. After matching, 52 patients remained in the TIVA-group and 92 in the INHA-group. Median PFS was 6 months in both groups. The median OS was 13.5 months in the TIVA-group and 13.0 months in the INHA-group. No significant survival differences associated with the type of anesthesia were found either before or after adjustment for known prognostic factors. This retrospective study supports the notion that the current anesthetic approaches employed during the resection of IDH-wildtype GBM do not impact patient survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10143-020-01452-7.
format Online
Article
Text
id pubmed-8490243
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-84902432021-10-15 The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients Schmoch, Thomas Jungk, Christine Bruckner, Thomas Haag, Sabine Zweckberger, Klaus von Deimling, Andreas Brenner, Thorsten Unterberg, Andreas Weigand, Markus A. Uhle, Florian Herold-Mende, Christel Neurosurg Rev Original Article Recent data suggest that the type of anesthesia used during the resection of solid tumors impacts the long-term survival of patients favoring total-intravenous-anesthesia (TIVA) over inhalative-anesthesia (INHA). Here we sought to query this impact on survival in patients undergoing resection of glioblastoma (GBM). All patients receiving elective resection of a newly diagnosed, isocitrate-dehydrogenase-1-(IDH1)-wildtype GBM under general anesthesia between January 2010 and June 2017 in the Department of Neurosurgery, Heidelberg University Hospital, were included. Patients were grouped according to the applied anesthetic technique. To adjust for potential prognostic confounders, patients were matched in a 1:2 ratio (TIVA vs. INHA), taking into account the known prognostic factors: age, extent of resection, O-6-methylguanine-DNA-methyltransferase-(MGMT)-promoter-methylation-status, pre-operative Karnofsky-performance-index and adjuvant radio- and chemotherapy. The primary endpoint was progression-free-survival (PFS) and the secondary endpoint was overall-survival (OS). In the study period, 576 patients underwent resection of a newly diagnosed, IDH-wildtype GBM. Patients with incomplete follow-up-data, on palliative treatment, having emergency or awake surgery; 54 patients remained in the TIVA-group and 417 in the INHA-group. After matching, 52 patients remained in the TIVA-group and 92 in the INHA-group. Median PFS was 6 months in both groups. The median OS was 13.5 months in the TIVA-group and 13.0 months in the INHA-group. No significant survival differences associated with the type of anesthesia were found either before or after adjustment for known prognostic factors. This retrospective study supports the notion that the current anesthetic approaches employed during the resection of IDH-wildtype GBM do not impact patient survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10143-020-01452-7. Springer Berlin Heidelberg 2020-12-22 2021 /pmc/articles/PMC8490243/ /pubmed/33354749 http://dx.doi.org/10.1007/s10143-020-01452-7 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Schmoch, Thomas
Jungk, Christine
Bruckner, Thomas
Haag, Sabine
Zweckberger, Klaus
von Deimling, Andreas
Brenner, Thorsten
Unterberg, Andreas
Weigand, Markus A.
Uhle, Florian
Herold-Mende, Christel
The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
title The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
title_full The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
title_fullStr The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
title_full_unstemmed The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
title_short The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
title_sort anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490243/
https://www.ncbi.nlm.nih.gov/pubmed/33354749
http://dx.doi.org/10.1007/s10143-020-01452-7
work_keys_str_mv AT schmochthomas theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT jungkchristine theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT brucknerthomas theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT haagsabine theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT zweckbergerklaus theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT vondeimlingandreas theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT brennerthorsten theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT unterbergandreas theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT weigandmarkusa theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT uhleflorian theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT heroldmendechristel theanesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT schmochthomas anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT jungkchristine anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT brucknerthomas anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT haagsabine anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT zweckbergerklaus anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT vondeimlingandreas anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT brennerthorsten anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT unterbergandreas anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT weigandmarkusa anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT uhleflorian anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients
AT heroldmendechristel anesthetistschoiceofinhalationalvsintravenousanestheticshasnoimpactonsurvivalofglioblastomapatients